BB
BB Biotech Portfolio holdings
AUM
$3.98B
This Quarter Return
+31.41%
1 Year Return
+15.06%
3 Year Return
+120.36%
5 Year Return
+263.74%
10 Year Return
–
AUM
$3.98B
AUM Growth
+$3.98B
(+27%)
Cap. Flow
-$512K
Cap. Flow
% of AUM
-0.01%
Top 10 Holdings %
Top 10 Hldgs %
64.68%
Holding
36
New
2
Increased
14
Reduced
6
Closed
1
Top Buys
| 1 |
CRISPR Therapeutics
CRSP
|
$29M |
| 2 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$23.4M |
| 3 |
Nektar Therapeutics
NKTR
|
$21.5M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$20.2M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$13.6M |
Top Sells
| 1 |
Ionis Pharmaceuticals
IONS
|
$82.5M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$25.5M |
| 3 |
Incyte
INCY
|
$16.2M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$13M |
| 5 |
Gilead Sciences
GILD
|
$12.4M |
Sector Composition
| 1 | Healthcare | 96.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $627M | 15.76% | 7,725,000 -1,016,334 | -12% | -$82.5M |
|
|
2
Incyte
INCY
$16.5B
| $311M | 7.83% | 3,620,000 -188,322 | -5% | -$16.2M |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $297M | 7.46% | 3,366,786 +23,696 | +0.7% | +$2.09M |
|
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $239M | 6.01% | 1,300,000 -70,445 | -5% | -$13M |
|
|
SAGE
5
DELISTED
Sage Therapeutics
SAGE
| $219M | 5.5% | 1,375,229 | – | – |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $208M | 5.22% | 2,200,000 -103,875 | -5% | -$9.8M |
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $201M | 5.05% | 2,978,134 +100,000 | +3% | +$6.74M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $178M | 4.47% | 1,314,428 | – | – |
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $152M | 3.83% | 1,631,089 +59,700 | +4% | +$5.58M |
|
10
Esperion Therapeutics
ESPR
$448M
| $141M | 3.56% | 3,522,964 +130,000 | +4% | +$5.22M |
|
|
RDUS
11
DELISTED
Radius Health, Inc.
RDUS
| $135M | 3.4% | 6,781,685 +71,409 | +1% | +$1.42M |
|
12
Halozyme
HALO
$8.56B
| $134M | 3.37% | 8,322,860 | – | – |
|
13
argenx
ARGX
$43.6B
| $113M | 2.84% | 904,739 +20,000 | +2% | +$2.5M |
|
14
Moderna
MRNA
$9.37B
| $97.4M | 2.45% | 4,785,681 | – | – |
|
|
MYOV
15
DELISTED
Myovant Sciences Ltd.
MYOV
| $85.9M | 2.16% | 3,597,882 | – | – |
|
|
ICPT
16
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $78M | 1.96% | 696,976 +121,257 | +21% | +$13.6M |
|
|
17
Gilead Sciences
GILD
$140B
| $74.3M | 1.87% | 1,142,204 -190,000 | -14% | -$12.4M |
|
|
18
Nektar Therapeutics
NKTR
$568M
| $67.9M | 1.71% | 2,020,676 +639,701 | +46% | +$21.5M |
|
19
Exelixis
EXEL
$10.1B
| $67.5M | 1.7% | 2,835,000 | – | – |
|
|
AKCA
20
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $67.4M | 1.69% | 2,377,638 -8,833 | -0.4% | -$250K |
|
|
MYOK
21
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $65.8M | 1.65% | 1,264,913 +387,647 | +44% | +$20.2M |
|
22
MacroGenics
MGNX
$112M
| $61.1M | 1.54% | 3,400,000 +116,728 | +4% | +$2.1M |
|
23
Wave Life Sciences
WVE
$1.53B
| $56.9M | 1.43% | 1,465,002 | – | – |
|
24
Voyager Therapeutics
VYGR
$186M
| $54.9M | 1.38% | 2,865,841 | – | – |
|
|
BOLD
25
DELISTED
Audentes Therapeutics, Inc
BOLD
| $53.4M | 1.34% | 1,369,604 +600,200 | +78% | +$23.4M |
|